Cited by

• Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.

  Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A. Krösser S, et al. Eur J Clin Pharmacol. 2006 Apr;62(4):277-84. doi: 10.1007/s00228-006-0101-7. Epub 2006 Mar 7. Eur J Clin Pharmacol. 2006. PMID: 16525816 Clinical Trial.
• Isolation, analysis and in vitro assessment of CYP3A4 inhibition by methylxanthines extracted from Pu-erh and Bancha tea leaves.

  Georgiev KD, Radeva-Ilieva M, Stoeva S, Zhelev I. Georgiev KD, et al. Sci Rep. 2019 Sep 26;9(1):13941. doi: 10.1038/s41598-019-50468-7. Sci Rep. 2019. PMID: 31558747 Free PMC article.
• Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

  Darby JK, Pasta DJ, Wilson MG, Herbert J. Darby JK, et al. Clin Drug Investig. 2008;28(9):553-64. doi: 10.2165/00044011-200828090-00002. Clin Drug Investig. 2008. PMID: 18666802
• The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

  Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. Rakhit A, et al. Eur J Clin Pharmacol. 2008 Jan;64(1):31-41. doi: 10.1007/s00228-007-0396-z. Epub 2007 Nov 14. Eur J Clin Pharmacol. 2008. PMID: 18000659 Clinical Trial.
• Membrane transporters in drug development.

  International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. International Transporter Consortium, et al. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028. Nat Rev Drug Discov. 2010. PMID: 20190787 Free PMC article. Review.